Zhenfan Yang

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations.

Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 13, 2024

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.

Journal: The Lancet. Oncology

Published: September 28, 2023

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.

Journal: The Lancet. Respiratory medicine

Published: July 06, 2023

Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants.

Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants.

Journal: Frontiers in immunology

Published: December 20, 2022

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 02, 2022

Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy.

Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 16, 2018

Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.

Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.

Journal: Thoracic cancer

Published: April 26, 2018

Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer.

Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer.

Journal: Oncology reports

Published: February 28, 2018

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

Journal: Science advances

Published: January 31, 2018

Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.

Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.

Journal: International journal of cancer

Published: September 30, 2017

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: September 06, 2017

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

Journal: The Lancet. Respiratory medicine

Published: August 11, 2017

Showing 1-12 of 18

Last Updated: 09/26/2026